TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11506108
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with 15 ml/kg crystalloid starting with the spinal anesthetic injection
Study: 3066854
Drug: Misonidazole (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (total dose of about 11 g/m2)
Study: 29996798
Drug: 5% duty
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% duty cycle (DC) subthreshold laser treatment
Study: 29996798
Drug: 15% duty
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% duty cycle (DC) subthreshold laser treatment
Study: 29996798
Drug: Continuous wave
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wave (CW) laser treatment
Study: 25190615
Drug: Intravenous potassium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous potassium replacement (IVPR)
Study: 17965109
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (4 mg/0.1 ml)
Study: 17965109
Drug: Bevacizumab (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.5 mg/0.06 ml)
Study: 12942187
Drug: Topical 17α-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 17α-estradiol
Study: 12942187
Drug: Topical immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical immunotherapy for alopecia areata
Study: 12942187
Drug: Modern broad
Normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern broad spectrum antimycotic agents for infectious scarring alopecias
Study: 11190013
Drug: ketorolac 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 0.5% ophthalmic solution
Study: 9001827
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray 200 micrograms once daily (n = 77)
Study: 9001827
Drug: Oral fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluticasone propionate 5 mg once daily (n = 73)
Study: 9001827
Drug: Oral fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluticasone propionate 10 mg once daily (n = 77)
Study: 31577081
Drug: i.v. combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. combination of ampicillin + sulbactam with daily cleaning of tonsillar lesions
Study: 31577081
Drug: i.v. combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. combination of ampicillin + sulbactam
Study: 29030111
Drug: LFMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFMS treatment (20 min/day for 4 days)
Study: 29030111
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (20 min/day for 4 days)
Study: 29030111
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (20 min/day for 2 days followed by LFMS treatment 20 min/day for 2 days)
Study: 2510191
Drug: L-Carnitina (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitina (1 g endovenous, per orally administered vials, tablets)
Study: 31897572
Drug: Treatment (alcohol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (alcohol, hypnotics, sleep deprivation)
Study: 31897572
Drug: Treatment-induced changes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced changes in SDLP
Study: 29984800
Drug: Loading of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading of the tympanic membrane with 340 mg (25 λ)
Study: 29984800
Drug: Loading of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading of the tympanic membrane with 544 mg (40 λ)
Study: 23623861
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration procedures without robot
Study: 20850390
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of normal saline
Study: 20850390
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of diprospan
Study: 20850390
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of diprospan+songmeile
Study: 19225122
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplements or own supplements)
Study: 16472562
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive (OC) use
Study: 16472562
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral contraceptive (OC) use
Study: 16472562
Drug: Post-OC discontinuation
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-OC discontinuation
Study: 10920614
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w antileprosy vaccine
Study: 8847984
Drug: Magnetic fields
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic fields (ELF‐MF) therapy, 20 procedures using Aplhatron 4100 device
Study: 8847984
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment (control group of 29 sawyers)
Study: 1575065
Drug: Chlorpheniramine, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 8 mg twice daily
Study: 1575065
Drug: Chlorpheniramine, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 12 mg twice daily
Study: 1575065
Drug: Terfenadine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 120 mg twice daily
Study: 1575065
Drug: Astemizole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, 10 mg/d
Study: 26885791
Drug: Common antiaging
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common antiaging topical treatments (prescription tretinoin, idebenone, kinetin, polyhydroxy, lactic and glycolic acids)
Study: 10623364
Drug: H2‐receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2‐receptor antagonist maintenance therapy with ranitidine (150 mg daily)
Study: 10623364
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy using an omeprazole/amoxicillin/metronidazole regimen
Study: 7582388
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1 and 250 mg on days 2-5)
Study: 6893819
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pirenzepine
Study: 6893819
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pirenzepine
Study: 7267679
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg atropine
Study: 18788415
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers
Study: 10672842
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg given 2 hours before ERCP
Study: 1603291
Drug: Oxiracetam 800
Normalized name: oxiracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam 800 mg b.i.d. for 90 days
Study: 1603291
Drug: Oxiracetam 800
Normalized name: oxiracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam 800 mg b.i.d. for 1 year (open follow-up)
Study: 1603291
Drug: Oxiracetam 800
Normalized name: oxiracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam 800 mg b.i.d. during late follow-up
Study: 29382675
Drug: Internet-delivered computerised
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered computerised cognitive-behavioural therapy (ICBT) as an adjunct to usual care (UC)
Study: 25893719
Drug: 568 ml
Normalized name: petrolatum 568 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 568 ml (1 pint) water preload
Study: 22734676
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment or usual care (Control)
Study: 22883445
Drug: Magnesium sulfate,
Normalized name: MAGNESIUM SULFATE,ANHYDROUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulfate, 100 mg epidurally before anesthesia induction and 500 mg added to the infusion postoperatively
Study: 22883445
Drug: Normal saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, 5 mL epidurally before anesthesia induction
Study: 20567177
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol every 4 hours, up to four doses
Study: 20567177
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol with isosorbide mononitrate every 6 hours, up to two doses
Study: 20567177
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol with isosorbide mononitrate
Study: 15367512
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg/day
Study: 15741421
Drug: Diet/lifestyle counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet/lifestyle counseling plus immediate fluvastatin 80 mg/day
Study: 15741421
Drug: Diet/lifestyle counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet/lifestyle counseling only, with initiation of fluvastatin 80 mg/day following occurrence of future nonfatal MACE
Study: 10232418
Drug: SK+early OP
Normalized name: OP-145
DrugBank: OP-145 (DB05672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK+early OP (early surgical drainage with adjunctive intrapleural fibrinolysis)
Study: 10232418
Drug: IP-SK (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP-SK (adjunctive intrapleural streptokinase)
Study: 8914031
Drug: ACE inhibitor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor, lisinopril (N = 18)
Study: 8914031
Drug: Nondihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondihydropyridine calcium channel blockers (NDCCBs), verapamil SR (N = 8) or diltiazem SR (N = 10)
Study: 8914031
Drug: Beta blocker,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker, atenolol (N = 16)
Study: 6195026
Drug: Dermovate ointment
Normalized name: clobetasol Topical Ointment [Temovate]
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dermovate ointment
Study: 6195026
Drug: Betnovate ointment
Normalized name: Betnovate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betnovate ointment (betamethasone valerate 0.1%)
Study: 6195026
Drug: Propaderm Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propaderm Forte cream (beclomethasone dipropionate 0.5%)
Study: 6195026
Drug: Propaderm ointment
Normalized name: beclomethasone dipropionate Topical Ointment [Propaderm A]
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propaderm ointment (beclomethasone dipropionate 0.025%)
Study: 6195026
Drug: Nerisone Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerisone Forte ointment (diflucortolone valerate 0.3%)
Study: 6195026
Drug: Nerisone ointment
Normalized name: Nerisone
DrugBank: Difluocortolone (DB09095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerisone ointment (diflucortolone valerate 0.1%)
Study: 6195026
Drug: Adcortyl ointment
Normalized name: triamcinolone acetonide Topical Ointment [Adcortyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adcortyl ointment (triamcinolone acetonide 0.1%)
Study: 6195026
Drug: Ledercort ointment
Normalized name: triamcinolone acetonide Topical Ointment [Ledercort]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledercort ointment (triamcinolone acetonide 0.1%)
Study: 6195026
Drug: Extemporaneous dilutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extemporaneous dilutions of Adcortyl and Ledercort ointments (triamcinolone acetonide 0.025%)
Study: 27599328
Drug: Bevacizumab nasal
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab nasal spray 25 mg
Study: 27599328
Drug: Bevacizumab nasal
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab nasal spray 50 mg
Study: 27599328
Drug: Bevacizumab nasal
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab nasal spray 75 mg
Study: 15890740
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg intranasal buserelin followed by 100 microg every 3 days (group B)
Study: 15890740
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg intranasal buserelin followed by 100 microg every 2 days (group C)
Study: 15890740
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg intranasal buserelin followed by 100 microg every day (group D)
Study: 17392540
Drug: Glimepiride (1-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-8 mg once daily)
Study: 3381638
Drug: Iodinated salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated salt (20 mg of iodine as iodate/kg salt consumed, assumed consumption of 5 g salt per day)
Study: 21605278
Drug: Iodopovidone (20mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodopovidone (20mL of a 10% solution)
Study: 16570572
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 microg bolus plus infusion at 250 microg/hour for 48 hours)
Study: 7914470
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 administered as a single dose over 1 hour
Study: 7914470
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 administered in divided daily doses for 3 days, each over 1 hour
Study: 27506677
Drug: Constraint-Induced Aphasia
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Aphasia Therapy (CIAT) for 3 hours per day (10 workdays, total 30 hours)
Study: 27506677
Drug: Conventional communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional communication treatment with same intensity without constraints
Study: 27506677
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy twice a day plus group therapy (total 14 hours)
Study: 25976708
Drug: Fast-setting polyvinyl
Normalized name: Polyvinyl Alcohol
DrugBank: Polyvinyl alcohol (DB11060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast-setting polyvinyl siloxane (PVS) impression material with heavy body/light body (HB/LB) combination (Imprint 4; 3M ESPE)
Study: 25976708
Drug: Conventional PVS
Normalized name: PV
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional PVS impression material with HB/LB combination (Imprint 3; 3M ESPE)
Study: 14731059
Drug: Zotepine (Nipolept)
Normalized name: zotepine
DrugBank: Zotepine (DB09225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (Nipolept) [12.5-150 mg/day]
Study: 11736772
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (0-300 microg x kg(‐1) x min(‐1))
Study: 11736772
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no esmolol infusion)
Study: 31255988
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (n=5)
Study: 26817175
Drug: Tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen citrate 20 mg/day
Study: 26817175
Drug: Tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen citrate plus Folate 5 mg/day
Study: 26817175
Drug: Folate 5
Normalized name: folate 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate 5 mg/day
Study: 24843716
Drug: Empagliflozin 5
Normalized name: empagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 5 mg
Study: 27929674
Drug: Empagliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (all doses)
Study: 18975504
Drug: Intramuscular placentrex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placentrex injection along with two-week conventional therapy
Study: 12846709
Drug: Dolasetron 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 0.35 mg.kg‐1
Study: 11772810
Drug: Dolasetron 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 12.5 mg
Study: 11151878
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg i.v. azathioprine over 36 h
Study: 11151878
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg i.v. azathioprine over 36 h
Study: 11151878
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg i.v. azathioprine as three 8‐h infusions over 3 days
Study: 9120123
Drug: Standard CVVHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CVVHD blood lines and heparin concentration (100 units/ml)
Study: 9120123
Drug: Modified circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified circuit design with heparin delivered in a more dilute volume (10 units/ml)
Study: 9120123
Drug: Pre-heparin APTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-heparin APTT
Study: 6326927
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No sodium bicarbonate supplement
Study: 24310049
Drug: Prescription opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription opioid analgesics (oral)
Study: 22701017
Drug: TPTD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPTD 20 μg once daily by sc injection
Study: 22701017
Drug: ZOL 5
Normalized name: danazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOL 5 mg by iv infusion
Study: 17959576
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care services (usual care plus standardized services from a clinical pharmacist, including an initial comprehensive in-home medication assessment and two follow-up visits)
Study: 15463834
Drug: Tobramycin nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin nebuliser solution (TNS) 300 mg by aerosol twice daily (b.i.d.)
Study: 9828870
Drug: Homeopathy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathy treatment for warts
Study: 9828870
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for warts
Study: 8466742
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg once daily)
Study: 1790542
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg twice daily)
Study: 19543129
Drug: Bazedoxifene 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 40 mg
Study: 17106318
Drug: Extended-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metoprolol tartrate
Study: 10878702
Drug: Postprandial changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial changes in glucose, insulin, triglyceride, and non‐esterified fatty acids (NEFA) after consuming a test meal containing 45% fat.
Study: 8933487
Drug: 5.5% CHO-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5% CHO-electrolyte solution (E)
Study: 8933487
Drug: 6.9% CHO-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% CHO-electrolyte solution (L)
Study: 21114603
Drug: Dapagliflozin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 50 mg with pioglitazone 45 mg
Study: 21114603
Drug: Dapagliflozin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 20 mg with metformin 1000 mg
Study: 21114603
Drug: Dapagliflozin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 20 mg with glimepiride 4 mg
Study: 21114603
Drug: Dapagliflozin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 20 mg with sitagliptin 100 mg
Study: 17096386
Drug: CCAP intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCAP intervention (combined cognitive‐behavioral therapy and pharmacotherapy)
Study: 9820380
Drug: PyloriTek test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PyloriTek test in cases without eradication therapy
Study: 9820380
Drug: PyloriTek test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PyloriTek test in cases with eradication therapy
Study: 9820380
Drug: PyloriTek test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PyloriTek test used more than 4 months after eradication therapy
Study: 35211
Drug: Amylobarbitone sodium
Normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylobarbitone sodium 100 mg
Study: 31583252
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of vitamin D3 daily for 30 consecutive months
Study: 31583252
Drug: CYP27B1 (rs10877012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP27B1 (rs10877012) G/T genotype
Study: 16446322
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 intravenously on day 1
Study: 16446322
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 intravenously on day 1 with raltitrexed 3 mg/m2